Products LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Phase 2/3 Completed 📈 Rising Nov 3, 2016 → Jan 3, 2022
About LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 is a phase 2/3 stage product being developed by Novartis for Pediatric Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT02678312. Target conditions include Pediatric Heart Failure.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02678312 Phase 2/3 Completed Nov 3, 2016 Jan 3, 2022 Pediatric Heart Failure
Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3
Other Products from Novartis